INONasdaq

INOVIO PHARMACEUTICALS, INC.

Healthcare·Oncology·Phase 3·Plymouth Meeting, PA, United States
OncologyImmunologyRespiratory

INOVIO PHARMACEUTICALS, INC. (INO): 7 pipeline candidates · 1 upcoming catalyst · ~5 mo cash runway · 4 clinical trials. Updated within the last hour.

5.6/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway1.4

5.2 months

Financial Health5.0

D/E 7.20 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth10.0

7 candidates

Catalyst Momentum3.0

1 upcoming, next in ~134d

Insider SignalN/A

N/A

A transparent, data-derived signal for INOVIO PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$92.6M

Cash

$26.3M

Quarterly Burn

$21.6M

Runway

5.2 mo

Revenue

$0

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Nov 2026
Today~7 mo out
Catalyst within runway

Pipeline (7 candidates)

Upcoming Catalysts (1)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

98

Total value held

$60.1M

HolderSharesValue
fmr llc9,339,614$16.3M
janus henderson group plc6,616,812$11.5M
vanguard capital management llc5,802,416$10.1M
d. e. shaw & co., inc.2,212,819$3.9M
adar1 capital management, llc1,470,108$2.6M
millennium management llc1,410,845$2.5M
adage capital partners gp, l.l.c.804,958$1.4M
geode capital management, llc801,504$1.4M
blackrock, inc.662,181$1.2M
renaissance technologies llc643,777$1.1M

Showing top 10 of 98 institutional holders of INOVIO PHARMACEUTICALS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

4 clinical trials·1 FDA decision·CEO: Dr. Jacqueline E. Shea Ph.D.

Frequently asked questions

How many drug candidates are in INOVIO PHARMACEUTICALS, INC.'s pipeline?

INOVIO PHARMACEUTICALS, INC. (INO) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is INOVIO PHARMACEUTICALS, INC.'s lead drug candidate?

INOVIO PHARMACEUTICALS, INC.'s most advanced tracked candidate is cemiplimab (Phase 1/Phase 2) for Glioblastoma.

What is INOVIO PHARMACEUTICALS, INC.'s next catalyst?

INOVIO PHARMACEUTICALS, INC.'s next tracked catalyst is a PDUFA event — "PDUFA Date: ino-3107" — expected October 30, 2026.

What is INOVIO PHARMACEUTICALS, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, INOVIO PHARMACEUTICALS, INC. has approximately 5.2 months of cash runway.

What is INOVIO PHARMACEUTICALS, INC.'s market capitalization?

INOVIO PHARMACEUTICALS, INC.'s market capitalization is approximately $92.6M.

Get the full picture on INOVIO PHARMACEUTICALS, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.